During the 2023 Florida Society of Clinical Oncology (FLASCO) Fall Session, several Florida Cancer Specialists & Research Institute, LLC (FCS) physicians were elected to serve as executive committee officers and chairs for the nationally recognized advocacy group in the upcoming term beginning January 1, 2024.
FCS is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM). The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body’s immune system to fight cancer.
Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute, LLC (FCS) are contributing to improving cancer care globally as they join fellow oncology professionals for the NCODA 2023 International Fall Summit in Orlando this week.
Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
FCS clinicians and senior leaders are among the industry experts who will present breakthrough data, research and clinical strategies at the Florida Society of Clinical Oncology (FLASCO) Fall Session in Orlando this month.
FCS Top News Updates
FCS Expands Footprint Into St. Lucie County, Breaks Ground For New Cancer Center in Tradition
Men’s Guide to Prostate ConditionsA comprehensive resource guide for men seeking to understand and maintain their prostate health.
FCS Celebrates Opening of New Clinic Location in DavenportFCS celebrated the opening of its new clinic location in Davenport with a ribbon-cutting ceremony on Thursday, November 9, 2023.
Several FCS physicians and leaders appointed to 2024 FLASCO executive committeesDuring the 2023 Florida Society of Clinical Oncology (FLASCO) Fall Session, several Florida Cancer Specialists & Research Institute, LLC (FCS) physicians were elected to serve as executive committee officers and chairs for the nationally recognized advocacy group in the upcoming term beginning January 1, 2024.
FCS physicians present at 2023 SITC ConferenceFCS physicians present at the Society for Immunotherapy of Cancer Annual Meeting in San Diego.
Bispecific Treatment For Multiple Myeloma Now Available In Sarasota CountyFCS is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM). The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body’s immune system to fight cancer.
FCS leaders present at NCODA 2023 Fall SummitPharmacy experts and leaders from Florida Cancer Specialists & Research Institute, LLC (FCS) are contributing to improving cancer care globally as they join fellow oncology professionals for the NCODA 2023 International Fall Summit in Orlando this week.
FCS physicians present findings at ESMO 2023Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
Leaders and physicians from FCS will participate in the 2023 FLASCO Fall SessionFCS clinicians and senior leaders are among the industry experts who will present breakthrough data, research and clinical strategies at the Florida Society of Clinical Oncology (FLASCO) Fall Session in Orlando this month.